Viral and Post-Infectious Mechanisms in ALS — Experiment Design

Experiment Overview

This experiment directly addresses ALS Knowledge Gap #15 (Score: 27/40): "What role do viral and post-infectious mechanisms play in a subset of sporadic ALS?" The gap highlights a significant but understudied area — while most ALS research focuses on genetic causes (~10% familial), emerging evidence suggests that viral infections may trigger or accelerate ALS in a substantial subset of patients.

Experiment Overview

This experiment directly addresses ALS Knowledge Gap #15 (Score: 27/40): "What role do viral and post-infectious mechanisms play in a subset of sporadic ALS?" The gap highlights a significant but understudied area — while most ALS research focuses on genetic causes (~10% familial), emerging evidence suggests that viral infections may trigger or accelerate ALS in a substantial subset of patients.

Related: [ALS Knowledge Gaps](/gaps/als) | [Viral and Post-Infectious Mechanisms in ALS](/mechanisms/viral-post-infectious-als) | [ALS Cure Roadmap](/therapeutics/als-cure-roadmap)

Background and Rationale

Evidence Supporting Viral Hypothesis in ALS

Multiple lines of epidemiological and molecular evidence support a potential viral contribution to ALS pathogenesis:

Knowledge Gap: What Is Missing

Despite suggestive data, key questions remain:

• Are viral detections in ALS brain incidental or pathogenic?
• What determines whether viral infection triggers ALS in susceptible individuals?
• Can antiviral therapy modify ALS progression?
• What is the interaction between viral infection and known ALS genes (SOD1, C9orf72, FUS)?

Study Design

Type

Hypothesis

Primary Hypothesis: A subset of sporadic ALS patients (~15-30%) has evidence of viral involvement in disease pathogenesis, characterized by:

Secondary Hypotheses:

• Viral-positive ALS patients may have distinct clinical phenotypes (e.g., earlier onset, different progression pattern)
• Antiviral therapy may slow progression in viral-positive subgroups
• Viral load/titer correlates with disease activity markers (NfL, pNfH)

Population

| Parameter | Value |
|-----------|-------|
| Total ALS patients | 500 |
| Sporadic ALS only | 100% (no family history) |
| Age range | 30-75 years |
| Disease duration | ≤24 months from symptom onset |
| Controls | 500 (age/sex-matched neurologically healthy) |

Inclusion Criteria

Exclusion Criteria

Biomarker Assessment

Viral Serology Panel

| Virus | Test | Rationale |
|-------|------|-----------|
| HSV-1 | IgG, IgM, avidity | Primary candidate - implicated in ALS[@als2024] |
| HSV-2 | IgG, IgM | Cross-reactivity assessment |
| HHV-6A/B | IgG, PCR (CSF) | Detected in ALS brain[@hhv62023] |
| HHV-6 (ciHHV-6) | ddPCR (blood) | Chromosomally integrated - reactivation risk |
| VZV | IgG, IgM | Can cause motor neuron infection |
| EBV | IgG, IgG avidity | Associated with neuroinflammation |
| CMV | IgG | Age-related seropositivity |
| SARS-CoV-2 | IgG, nucleocapsid | Long-COVID neurological sequelae[@covid2024] |

CSF Analysis

| Marker | Purpose |
|--------|---------|
| Viral PCR panel | Detect viral DNA/RNA in CSF |
| NfL, pNfH | Neurodegeneration markers |
| IL-6, IL-1β, TNF-α | Neuroinflammation |
| Viral-specific IgG index | Intrathecal antibody production |

Tissue Analysis (Postmortem)

• Laser capture microdissection of motor cortex
• Viral DNA/RNA detection by PCR and RNA-seq
• Co-localization with TDP-43 pathology
• Spatial transcriptomics for viral-associated gene signatures

Clinical Phenotype Characterization

Baseline Assessments

| Assessment | Timepoints |
|------------|------------|
| ALS-FRS-R | Baseline, 3, 6, 12, 24 months |
| Slow vital capacity | Baseline, 6, 12, 24 months |
| Timed Up-and-Go | Baseline, 6, 12, 24 months |
| MoCA | Baseline, 12, 24 months |
| Patient-reported outcomes | Baseline, 3, 6, 12 months |

Subgroup Analysis

Compare viral-positive vs viral-negative ALS on:

• Age of onset
• Site of onset (bulbar vs limb)
• Progression rate (ALSFRS-R slope)
• Survival from symptom onset
• Cognitive involvement (FTD comorbidity)

Therapeutic Intervention Arm (Optional Extension)

Rationale

Trial Design: Randomized, double-blind, placebo-controlled Population: Viral-positive ALS patients (n=60, 30 per arm) Intervention: Valacyclovir 1g BID vs placebo for 12 months Endpoints:

• NfL trajectory
• ALSFRS-R decline rate
• Viral serology titers
• CSF inflammatory markers

Statistical Analysis

Primary Analysis

• Chi-square test for viral seropositivity rate: ALS vs controls
• Logistic regression: Viral status ~ ALS status + age + sex + genetics

Secondary Analysis

• Cox proportional hazards: Survival ~ viral status + covariates
• Mixed models: ALSFRS-R trajectory ~ viral status × time

Sample Size Justification

• Expected viral positivity rate in controls: 60%
• Expected viral positivity rate in ALS: 75%
• Power 80%, α=0.05: n=425 per group
• Allowing for 15% dropout: n=500 per group

Scoring

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Impact | 8 | Could reveal trigger mechanism in subset of ALS |
| Cure Proximity | 6 | Antiviral therapy is available; if effective, readily translatable |
| Feasibility | 7 | Standard serology and PCR assays available; multicenter coordination needed |
| Cost Efficiency | 7 | Biomarker panel relatively low cost; high-impact if positive |
| Timeline | 8 | Serology/CSF results within 6 months; long-term follow-up 2+ years |
| Cross-Disease Value | 7 | Findings may inform AD, PD viral hypotheses |
| Biomarker Enablement | 6 | Viral markers could serve as patient stratification biomarkers |
| Combinability | 7 | Could combine with anti-inflammatory or neuroprotective therapies |
| De-risking Value | 7 | If positive, de-risks larger antiviral trials; if negative, closes this hypothesis |
| Novelty | 8 | Direct test of viral hypothesis in ALS - still controversial |

Total: 71/100

Risks and Limitations

Expected Outcomes

References